Short Interest in Grifols, S.A. (NASDAQ:GRFS) Drops By 9.7%

Grifols, S.A. (NASDAQ:GRFS) was the recipient of a large decrease in short interest during the month of September. As of September 30th, there was short interest totalling 4,570,000 shares, a decrease of 9.7% from the September 15th total of 5,060,000 shares. Currently, 1.8% of the shares of the company are short sold. Based on an average daily volume of 1,470,000 shares, the days-to-cover ratio is currently 3.1 days.

Institutional Trading of Grifols

Several institutional investors and hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC raised its position in Grifols by 49.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 1,135 shares during the last quarter. NBC Securities Inc. lifted its stake in shares of Grifols by 2.8% in the 3rd quarter. NBC Securities Inc. now owns 52,181 shares of the biotechnology company’s stock worth $463,000 after acquiring an additional 1,433 shares during the period. Creative Planning lifted its stake in shares of Grifols by 26.4% in the 3rd quarter. Creative Planning now owns 17,319 shares of the biotechnology company’s stock worth $154,000 after acquiring an additional 3,614 shares during the period. Team Hewins LLC lifted its stake in shares of Grifols by 11.8% in the 1st quarter. Team Hewins LLC now owns 40,818 shares of the biotechnology company’s stock worth $273,000 after acquiring an additional 4,324 shares during the period. Finally, Bank of Montreal Can lifted its stake in shares of Grifols by 12.4% in the 2nd quarter. Bank of Montreal Can now owns 70,640 shares of the biotechnology company’s stock worth $446,000 after acquiring an additional 7,786 shares during the period.

Grifols Stock Performance

GRFS stock remained flat at $8.49 on Thursday. 138,321 shares of the company traded hands, compared to its average volume of 1,979,071. The firm’s 50-day simple moving average is $8.52 and its 200 day simple moving average is $7.65. Grifols has a 1 year low of $5.30 and a 1 year high of $12.15. The stock has a market capitalization of $5.84 billion, a PE ratio of 8.32 and a beta of 0.50. The company has a current ratio of 1.68, a quick ratio of 0.80 and a debt-to-equity ratio of 1.06.

Grifols (NASDAQ:GRFS) last released its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.23 by ($0.21). The company had revenue of $1.96 billion for the quarter. As a group, equities analysts forecast that Grifols will post 0.79 EPS for the current fiscal year.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.